Login to Your Account


China’s Taxus Pharma buys Cardium to get a foothold in regenerative medicine

By Shannon Ellis
Staff Writer

Wednesday, March 5, 2014

SHANGHAI – Privately held Shanxi Taxus Pharmaceuticals Co. Ltd., a subsidiary of Shenzhen Forntsea Taxus Industry Capital Management, will acquire majority shares in innovative drug developer Cardium Therapeutics Inc. (CRXM), of San Diego, for $5 million in cash.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription